Testing

Brain Scans Identify Two Regions That Shrink before the Hippocampus

Researchers found volume loss in the entorhinal cortex and amygdala up to a decade before clinical memory symptoms appear.

Published November 17, 2026 Read 3 min 541 words Topic Testing
Reviewed by: Dr. Michael Teplitsky, MD · November 2026

Two Brain Regions Show Atrophy before Hippocampal Volume Loss

Two specific brain regions begin shrinking before tissue loss reaches the hippocampus in people with Alzheimer's disease. Researchers at Johns Hopkins University analyzed brain imaging data and found that the entorhinal cortex and the amygdala deteriorate earlier than the primary memory center where clinicians usually look for damage. The entorhinal cortex handles the retrieval of old memories, while the amygdala processes emotional memory.

The investigators presented their findings at Neuroscience 2026, the annual meeting of the Society for Neuroscience, with full results published in the journal NeuroImage: Reports. Senior author Michael Miller noted that structural atrophy manifests in these areas as much as a decade before clinical memory loss starts. Detecting early tissue changes gives scientists a clearer window into how neurodegeneration develops over five to ten years.

Study Cohorts and Imaging Evidence across Disease Stages

The findings come from an analysis of hundreds of brain scans tracked over time across two independent study groups. The research team evaluated imaging from the Alzheimer's Disease Neuroimaging Initiative and the Biomarkers of Cognitive Decline Among Normal Individuals study. The data included scans from participants who remained symptom-free, individuals experiencing cognitive impairment, and patients who ultimately died from Alzheimer's disease.

Researchers used both Magnetic Resonance Imaging (MRI) and Positron Emission Tomography (PET) to measure structural changes. Across both patient cohorts, the entorhinal cortex and the amygdala showed greater volume loss relative to the hippocampus during early disease stages. The team also observed that gray matter atrophy was spatially localized with tau protein accumulation detected through PET scans and digital pathology.

Earlier Risk Assessment and Implications for Timely Intervention

Measuring volume loss in both regions together could serve as an early imaging biomarker to identify people at high risk for dementia. Researchers emphasize that therapies under study are likely to work best when started years before extensive brain damage causes cognitive symptoms. Co-author Meaghan Morris noted that tracking these anatomical changes could improve risk stratification, helping clinicians determine who will develop cognitive decline in the near future.

The study authors suggested that routine scans could eventually evaluate these two regions in individuals in their 30s and 40s who have a family history of Alzheimer's disease. For readers tracking metabolic and cardiovascular factors that influence neurodegenerative risk, earlier biomarkers clarify the timeframe in which preventive strategies must operate. Interventions intended to protect brain tissue need to occur during the silent window of neurodegeneration rather than waiting for memory symptoms to emerge.

Current Research Limitations and Required Molecular Mapping

These imaging markers cannot yet be used in routine clinical practice to diagnose individual patients. The study authors stated that additional research is required to understand the underlying molecular events that drive tissue loss in these two brain structures as pathology begins. Further validation is also necessary across broader community populations before standardized diagnostic thresholds can guide clinical care.

Patients concerned about dementia risk should discuss cognitive health and family history directly with a qualified physician. While structural imaging reveals when brain regions lose volume, standard clinical evaluations rely on validated cognitive tests, laboratory work, and established diagnostic criteria. Future trials will need to confirm whether treating patients based on early entorhinal and amygdala atrophy alters long-term clinical outcomes.

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making changes to your health regimen.
Primary source: View original source — referenced for fact-checking; this analysis is independent editorial content.
Found this useful?

Related Articles

Want these markers actually tested and explained?

Opt Health draws 55+ biomarkers at home or at one of 2,000+ lab locations, then a physician sits down with the results and tells you what they mean for you — not just whether they're inside the reference range.

See what Opt Health tests →

Topic updates

Get the weekly lab marker roundup

Blood test interpretation, optimal ranges, fasting insulin, A1C, thyroid panels, testosterone, cortisol, and nutrient markers.

No spam. Unsubscribe anytime.

Understand Your Health Better

Our free assessment maps your symptoms to the most relevant guides, tools, and product recommendations.

Take the Free Assessment →

Free · Takes 5 minutes · Instant results